Published in

Wiley Open Access, Thoracic Cancer, 2(6), p. 224-226, 2015

DOI: 10.1111/1759-7714.12171

Links

Tools

Export citation

Search in Google Scholar

Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma

Journal article published in 2014 by Hayoung Choi ORCID, Jinsun Chang, Hong‐Joon Shin, Cheol‐Kyu Park, In‐Jae Oh, Kyu‐Sik Kim, Young‐Chul Kim
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

We report a case showing the long-term clinical benefit of the continued use of gefitinib in a patient with asymptomatic progression of lung adenocarcinoma harboring an exon 19 deletion of the epidermal growth factor receptor gene. Although follow-up studies showed smoldering progression of metastatic lesions, continued treatment with gefitinib controlled pulmonary adenocarcinoma for more than six years.